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The dose-response relationship ofthe benzene covalent interaction with biological macromolecules from
ratorgans was studied. Theadministereddose rangewas 3.6 x 107 startingfromthe highestdosage employed,
486 mg/kg, which is oncogenic for rodents, and included low and very low dosages. The present study was
initiallyperformed with tritium-labeled benzene, administered by IP injection. In orderto exclude thepos-
sibility that part ofthe detected radioactivity wasdue to tritium incorporated into DNAfrom metabolic pro-
cesses, "4C-benzene was then also used following a similar experimental design. By HPLC analysis, a sin-
gle adduct from benzene-treated DNA was detected; adduct identification will be attempted in the nearfuture.
Linear dose-response relationship was observed within most ofthe range ofexplored doses. Linearity was
particularly evident within low and very low dosages. Saturation ofbenzene metabolism did occur at the
highestdosages formostoftheassayedmacromolecules andorgans, especially in ratliver. Thisfindingcould
be considered as indicative ofthe dose-response relationship oftumor induction and could be used in risk
assessment.
Introduction
Many data are available on benzene toxicity and car-
cinogenicity. The primary reason for the interest in the
behavior ofthis chemical is the widespread occupational
and environmental human exposure because ofits large
production and use (1). Toxic effects ofbenzene on bone
marrow and blood cells have been observed both in ro-
dents and humans; anemia, lymphocytopenia, and bone
marrow aplasia are the most frequent diseases. Carcino-
genic action, however, seems to have differenttargets in
humans (with the induction ofacute myelogenous leuke-
mia) and rodents (induction ofZymbalgland, oral cavity,
and stomach carcinomas, hepatocarcinomas, and lym-
phoid tumors mainly). Nevertheless, evaluation ofthe all
available experimental and epidemiological carcinogenic-
ity data, from a recent workby Grilli et al. (2), points out
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a similar saturable metabolism of benzene both for ro-
dentsand man. Saturationoccursfollowinginhalationex-
posure to dosages rangingfrom 10 to 100 ppm. The flat-
tening of the dose-response curve seems to suggest
carcinogenic activity at low doses 2- to 3-fold higherthan
thatreckonedbylinear extrapolationfromdatainthe 100
ppm range. Thus, evaluation of the dose-response rela-
tionship at low doses is very useful; it is a hard task, al-
thoughthe assessment ofthe associatedrisktohumanoc-
cupational and, mostly, nonoccupational exposure is a
matter ofgreat interest (3).
Benzene is a weak genotoxic compound that forms in
vivo adducts to rat and mouse liver DNA. The covalent
bindingindex(CBI)ofbenzene calculatedinratliverac-
cording to Lutz (4) is in the order ofunits (5). The CBI
allows an evaluation ofpre-initiatingactivityofcompound
in a dose range ofabout 106-fold and is sensitive enough
to explore low doses. Because ofits high sensitivity and
ofthe appreciable correlation with carcinogenicity data
(6), this test hasbeenpreviously employedforthe evalu-
ation of aromatic amines, nitrosamines, polycyclic aro-
matic hydrocarbons, and aflatoxins (7). All these chemi-
cals require metabolic activation and affect the early
stages of carcinogenesis (initiation).
In this paper, we aimed at quantifying the number ofMAZZULLO ETAL.
in vivo adducts to rat DNA of five organs showing dif-
ferent susceptibility to carcinogenesis by this compound.
Furthermore, the amount ofadducts as afunction ofthe
employed dosage was evaluated in orderto obtain a sur-
rogate forthe cancer dose-response curve in the range of
low and very low doses that cannot be exploredbylong-
term assays.
Materials and Methods
Groups of six male Wistar rats (220-250 g) were in-
jected IPwith 3H-labeled benzene (0.5to 108 *Ci/animal,
radiochemical purity 98%) purchased from The Radi-
ochemical Centre (Amersham, UK); six animals served
as a control group. Specific activity of 3H-benzene was
11.6 Ci/mmole; whennecessary the activity waslowered
byaddingcoldbenzene according totheexperimentalde-
sign. Dosages employed are shown in Tables 1 to 5.
Fasted animalswerekept in anair-conditioned roomwith
a dark-light cycle of12 hrandkilled 22 hrafterinjection.
Liver, spleen, kidney, lung, and stomachwere collected
from each animal andprocessed in orderto obtain DNA,
RNA, and proteins. Livers were pooled and processed
two by two in order to obtain triplicate values. For the
otherorgans, poolsfrom animalsofeach dose groupwere
processed. Aliquots(about 100mg)fromeachtissuewere
dissolved in 1 mL lumasolve (Landgroof, the Nether-
lands) at 400C in order to measure benzene distribution
to various organs as afunction ofthe administered dose.
Ten milliliters ofReady-Solve NA (Beckman Analytical,
Milan, Italy) and 0.1 mL acetic acid were added to each
scintillation vial in order to avoid chemoluminescence ef-
fects. Samples were stored at 0 to 5C for 2 days and
counted in a Beckman LS-1801 liquid scintillation spec-
trometer.
DNA, RNA, and proteins were isolated by phenol ex-
traction. Glycogen was carefully removed from liver
DNAbytreatmentwithmethoxyethanoland hexadecyl-
trimethyl ammonium bromide, according to the method
by Kinoshita and Gelboin (8). Macromolecules were ex-
haustively washed with organic solvents until all non-
covalently bound radioactivity was removed. DNA and
RNA recovery and purity were determined by specific
colorimetric reactions and ultraviolet absorption mea-
surement (5).
Aliquots of 10 to 20 mg DNA and 3 to 4 mg proteins
were dissolved in 1 mL lumasolve at400C and stored at
0to50Cfor2 days. Aceticacid0.5mL, and 10mL Ready-
Solv NA were added to samples dissolved in lumasolve,
whichwere counted as described above. RNA, 2 to 5mg
aliquots, dissolved in 1 to 1.5 mL buffer (pH 7.0), were
countedinscintillation vialscontaining 10mL Ready-Solv
MP (Beckman Analytical). All vials were counted 3 to 6
times foraminimumof20min. Atleast2000countswere
measuredforeach samplewith abackground ofabout 15
cpm and an efficiency ofabout33%.Appropriate controls,
performed with macromolecules extracted from un-
treated rats, were systematically counted. The control
macromolecules, like allsamplesfromthelowest assayed
dose, gave rise to counts similar from a statistical point
ofview to the instrumentbackground. Bindingvalues to
DNAcould notbe detectedatthe twolowest doses since
the method is not sensitive enough to detect any effect
at these doses. On the contrary, covalent bindingofben-
zene to RNA andproteins couldbe measured even after
administration of 1.04 x 10-6 mmole/kg of compound.
More recently, a study with 14C-benzene (purchased
from The Radiochemical Centre, specific activity 120.5
mCi/mmole, radiochemical purity 99%) was performed,
using an analogous schedule as thatpreviously described
for 3H-benzene. The dosagesof6.23 x 10-6,6.23 x 10 5,
1.97 x 10-4, 6.23 x i0-4, 1.97 x 10-3, 6.23 x 10-3, 6.23
x 10-2, 6.23 x 10 - l, and 6.23 mmole/kg have been ad-
ministered to groups of animals. Another animal group
served as control. 1"C-benzene, 0.178 to 357MiCi, perani-
mal was applied. Macromolecules were processed as
reported previously and their labelings were measured
as described in the experimental design carried outwith
3H-benzene, with a background ofabout 40 cpm and an
efficiency of about 94%.
HPLC analysis of5'-mononucleotides from liver DNA
of animals injected with 6.23 x 106 to 6.23 x 10- l
mmole/kg 3H-benzene and with 6.23 x 10 -2 mmole/kg
"4C-benzene wasperformed. Sixmilligrams ofDNAwere
treatedwith 0.6mgDNAse type 1 (SigmaChemical Co.,
St. Louis, MO) at 370C for3 hr in 3.0 mL of0.1 M potas-
siumphosphate-5mM MgCl2 -5mM CaCl2buffer, pH 7.0.
ThenpH wasraisedto 9.0and0.6 mgphosphodiesterase
type 1 (Sigma)from Crotalus atroxwasadded tothemix-
ture. Digestion was carried out for 24 hr at 370C.
5'-mononucleotides from 6 mg DNA were loaded on a
preparative ion exchange Ultrasil-Ax column (Serva,
Heidelberg, WestGermany, dp 5,pm, diameter: 9mm, L
250 mm), which was eluted with 0.01 M potassium phos-
phate buffer * HCl, pH 3.1, by means of a Beckman
HPLC system (flow: 1.5 mL/min): pump model 114, ab-
sorbance detector model 160, controller model 421. For
each case, 802-mL fractions were collected. UV absorp-
tion at 254 nm and radioactivity of each fraction was
measured.
Results
The amountofbenzene detected invarious organswas
alwaysproportional to the administered dose. Whatever
dosage was employed, the amount ofradioactivity mea-
sured in the liver was about 0.2% of the administered
dose. About 0.01% ofadministered benzene wasfoundin
kidney and 0.001% in the other assayed organs.
Bindingvalues of3H-benzene to RNAfrom various or-
gans were usually one order of magnitude higher than
those to DNA. Protein labeling was lower than that of
RNA and higher than that ofDNA (Table 1). The dose-
response relationship waslinear in the case ofliver DNA
within arange ofchangingby 105-fold(6.23 x 10 6-6.23
x 10- 1 mmole/kg). At a 10-fold higher dosage (6.23
mmole/kg) saturation ofbenzenebindingactivity was ob-
served as shown in Figure 1 (logarithmic scale). This ef-
fect would be even more evident in normal scale. More-
over, inthe caseofboth RNAandproteinbinding, amore
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Table 1. Dose-repsonse relationship of in vivo binding of 3H-benzene to biological macromolecules from rat liver.
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Adducts, pmole/mg
Dose, mmole/kg DNA RNA Protein
1.73 x i0-7 UDa UD UD
1.04 x 10-6 UD 1.29 x 10-4 ± 0.09 X 10-4 3.74 x 10-s ± 1.98 x lo-5
6.23 x 10-6 3.11 x 1-0 ± 2.36 x 10-5 1.42 x 10-' ± 0.25 x 10-3 2.56 x 10-4 + 0.71 x 10-4
(1.62)b
1.97 x 10- 6.84 x 10-5 + 4.18 x 10-5 3.56 x 10- ± 0.11 X 10-3 6.94 x 10-4 0.18 x 10-4
(1.13)
6.23 x 10-5 2.74 x 10-4 ± 0.25 x 10-4 1.50 x 10-2 + 0.52 x 10-2 2.34 x 10- ± 0.34 x 10-3
(1.43)
6.23 x 10-4 2.74 x 10-3 + 0.23 x 10-3 9.29 x 10-2 + 2.98 x 10-2 2.70 x 10-2 ± 0.39 x 10-2
(1.43)
6.23 x 10-3 1.55 x 10-2 ± 0.37 x 10-2 9.19 x 10-' + 2.43 x 10'- 2.67 x 10-1 ± 0.19 x 10-'
(0.81)
6.23 x 10-2 2.47 x 101' ± 0.77 x 10-1 9.33 ± 1.20 2.67 ± 0.26
(1.29)
6.23 x 10-' 2.65 ± 0.33 4.76 x 101 ± 1.14 x 10' 1.81 x 10' ± 0.27 x 10'
(1.38) (0.86)c
6.23 1.05 x 10' ± 0.34 x 10' 1.80 x 102 ± 0.65 x 102 7.02 x 101 ± 0.23 x 101
(0.55)
aUD, undetectable. The labeling values were not significantly different from those of controls. They were used as blanks and taken away from
labeling values of the other dosages.
bNumbers in parentheses are the covalent binding index; value calculated according to Lutz (4). C,Amole/mole DNA-phosphate calculated according to Swenson and Lawley (19).
appreciable saturation effect was observed starting from
the dose 6.23 x 101- mmole/kg. Thus, a linear dose-
response relationship was found within a range of 6 x
104-fold. The experimentwith "4C-benzene isinprogress.
Nevertheless, thelabelingsofliver macromoleculeswere
on the same levels as those detected when using 3H-
benzene. Also, their variation as a function of the em-
ployed dosage is linear up to the two highest dosages.
Due to the lower specific activity of the 14C-benzene,
binding to macromolecules was detected within a more
limited range of dosages (Table 2).
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FIGURE 1. Dose-response relationship between 3H-benzene dose and amount of adducts with DNA (O ...0), RNA (O--O) or proteins (A E -. A) of
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Table 2. Dose-response relationship of in vivo binding of '4C-benzene to biological marcomolecules from rat liver.
Adducts, pmole/mg
Dose, mmole/kg DNA RNA Protein
6.23 x 10- 6 UDa UD UD
6.23 x 10-I UD UD UD
1.97 x 10-4 UD 7.48 x 10-2 + 1.12 x 10-2 UD
6.23 x 10-4 UD 1.60 x 10- + 0.10 x 10-' 7.10 x 10-2 + 1.49 x 10-2
1.97 x l0o- 2.35 x 10-2 + 0.22 x 10-2 3.40 x 10- + 0.97 x 10-' 3.17 x 10-1 + 0.34 x 101-
(3.90)b
6.23 x 10-s 3.74 x 10-2 + 0.56 x 10-2 1.40 + 0.28 6.17 x 10-' + 0.11 x 10-'
(1.95)
6.23 x 10-2 3.03 x 10-' + 0.28 x 101- 1.17 x 10' + 0.09 x 101 4.95 + 0.17
(1.60)
6.23 x 10- 1.16 + 0.15 6.28 x 10' + 1.16 x 101 2.43 x 10' + 0.12 x 101
(0.60)
6.23 4.62 + 0.56 1.31 x 102 + 0.05 x 102 3.10 x 10' + 0.35 x 101
(0.24)
aUD, undetectable. The labeling values were not significantly different from those of controls. They were used as blanks and taken away from
labeling values of the other dosages.
bNumbers in parentheses are covalent binding index (CBI); value calculated according to Lutz (4). A CBI value of7 was measured in a previous
study by Arfellini et al. (5) after administration of 6.35 x 10 3 mmole/kg of '4C-benzene.
organs as well as to RNA and proteins of stomach and
spleen (Tables 3 and 4) was a linear function of the ad-
ministered dose within the range ofthe technique sensi-
tivity (changing up to 106-fold in the case of stomach
DNA). Tendency to a saturation ofmetabolism was ob-
served, toalesserextentthaninliver, inthe caseofRNA
andproteins ofkidney andlung(Tables 5and 6). Indeed,
saturation was shown in protein labeling when employ-
ing the two highest doses.
The extent of3H-benzene bindingto DNA was similar
in all assayed organs. CBI values ranged from 1 to 2.
Values less than 1 were obtained inlung DNAonly. As-
suming a random interaction of benzene with DNA
molecules, DNAadducts densityrangedfrom 1 per 10-
nucleotides to 0.9 per 10-6 nucleotides.
The slope ofthe regression lines (DNAadducts versus
dose, in normal scale) was lower in the liver than in the
other target sites (data not shown). This finding is con-
sistentwith thehigher degree ofDNAbinding saturation
in this organ.
By HPLC analysis, a single adduct was detected in
liver DNA (Fig. 2). All radioactivity covalently bound
seems to be associated withthe lastelutingpeak, which
wasnotcoincidentwith thosefrombenzene,tritiatedwa-
ter, ornormalnucleotides. The samechromatographic be-
haviorwasfoundwhen analyzingliverDNAfromanyas-
sayed dose group regardless of the applied dosage.
Discussion
Due to the weak genotoxicity of the chemical, in the
first experiment, tritium-labeled benzene was employed
for its specific activity higher than that of "4C-benzene.
In consequence, we were able to investigate the extent
of benzene binding using a wide range of doses.
31 41 51
Fractions Number
m 2
Cn
FIGURE 2. HPLC analysis of5'-mononucleotides from liver DNA. Dashed line represents the UV-absorption of5'-mononucleotides from 6 mgliver
DNA of animal treated with 3H-benzene (6.23 x 10 1 mmole/kg) or '4C-benzene (6.23 x 10-2 mmole/kg). Solid line represents the chromato-
graphic behaviorofthe standard5'-mononucleotides, given as reference. In-such achromatographic systemtritiated waterelutes atthe fraction
5 and benzene at the fraction 6.
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Table 3. Dose-response relationship of in vivo binding of 3H-benzene to biological macromolecules from rat stomach.
Dose, mmole/kg
1.73 x 10-7
1.04 x 10-6
6.23 x 10-6
1.97 x 10-5
6.23 x 105
6.23 x 10-4
6.23 x 10-3
6.23 x 10-2
6.23 x 101-
6.23
DNA
UDa
UD
3.10 x 10-'
(1.62)b
NDC
3.74 x 10 4
(1.95)
4.03 x i0-3
(2.10)
5.35 x 10-2
(2.79)
4.62 x 10-1
(2.41)
3.32
(1.73)
3.59 x 101
(1.87)
Adducts, pmole/mg
RNA
UD
6.07 x 10-5
4.36 x 10-4
1.20 x 10-3
3.26 x 10-3
4.11 x 10-2
3.30 x 10 -'
3.18
4.04 x 101
5.04 x 102
Protein
UMY
8.09 x 10-5
1.51 x 10-4
ND
7.96 x i0-4
8.22 x 10-3
6.29 x 10-2
8.46 x 10-'
7.77
5.07 x 101
'UD, undetectable (see footnote a of Table 1).
bNumbers in parentheses are covalent binding index; value calculated according to Lutz (4).
CND, not determined (lost by accident).
Nevertheless, the possibility that a small amount oflabel-
ingcouldbe due tothe incorporationoftritium into DNA,
from water formed duringmetabolicprocesses, has tobe
considered. According to the report by Lutz and Schlat-
ter(9), only avery smallpercentage oftritiated wateris
incorporated. The incorporation of3H-water into normal
nucleotides was, however, excludedbyHPLC analysis of
5'-mononucleotides from 3H-benzene treated liver. It
showed the presence ofa single adduct whose identifica-
tion will be attempted in the near future. Probably,
dGMP or dAMP are involved in adduct formulation, as
shown invitro, by Snyder et al. (10)byusing mitoplasts.
The covalent binding of benzene to DNA, RNA, and
proteins from all assayed organs was measured at
dosages up to 6.23 mmole/kg (486 mg/kg) body weight
(about 1/6 ofLD50), some ofwhich were higherthanthose
capable ofinducingtumors(50mg/kgwhen administered
lifetimebygavage). Bindingvalueswereratherlow. Data
on 3H-benzene interaction with liver DNA are compara-
ble to those determined in the second experiment (in
progress)performedwith 14C-labeledbenzene. The mean
ofCBI in rat liver DNA (CBI = 1.2 and 1.7, for 3H- and
"4C-benzene, respectively) was slightly less than that
measured in aprevious report(5)with asingle dose(6.35
,umole/kg) of1"C-benzene. Benzene binds to various mac-
romolecules in different organs to similar levels. Ten-
dency to saturation is even more evident when employ-
ing 4C-benzene whose binding to liver DNA already
reaches saturation at a dosage of6.23 x 10 - 1 mmole/kg.
The extent of binding of lung macromolecules was
Table 4. Dose-response relationship of in vivo binding of 3H-benzene to biological macromolecules from rat spleen.
Dose, mmole/kg
1.73 x 10-7
1.04 x 10-6
6.23 x 10-6
1.97 x 105
6.23 x 10-
6.23 x 10-4
6.23 x 10-3
6.23 x 10-2
6.23 x 10-'
6.23
DNA
UDa
UD
(0.51)b
9.75 x 10-6
(0.51)b
8.88 x 10-
(1.47)
2.30 x l0-4
(1.20)
3.18 x -3
(1.66)
2.77 x 10-2
(1.45)
3.35 x 10-1
(1.75)
2.76
(1.45)
2.03 x 101
(1.07)
Adducts, pmole/mg
RNA
UD
UD
1.20 x 10-3
1.98 x 103
4.83 x 10-3
4.29 x 10-2
4.76 x 10-'
Protein
UD
1.55 x 10-
9.55 x 10 -5
NDC
1.01 x 10-3
1.08 x 10-2
2.33 x 10-'
4.17 1.08
3.04 x 101 6.15
6.63 x 10' ND
'UD, undetectable (see footnote a of Table 1).
bNumbers in parentheses are covalent binding index; value calculated according to Lutz (4).
CND, not determined (lost by accident).
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Table 5. Dose-response relationship of in vivo binding of 3H-benzene to biological macromolecules from the rat kidney.
Adducts, pmole/mg
Dose, mmole/kg DNA RNA Protein
1.73 x 10- 7 UDa UD UD
1.04 x 10-6 UD UD 3.86 x 1i-0
6.23 x 10-6 UD 1.56 x 10- 3.46 x 10-4
1.97 x 10-5 UD 1.31 x 10-2 NDc
6.23 x 10-5 2.34 x 10-4 3.22 x 10-2 2.99 x 10-
(1.22)b
6.23 x 10-4 2.06 x 10- 4.16 x 10' 2.83 x 10-2
(1.07)
6.23 x 1i-0 ND ND ND
6.23 x 10-2 7.57 x 10' 1.60 x 10' 3.34
(3.95)
6.23 x 10' 2.57 4.16 x 102 1.58 x 101
(1.34)
6.23 2.65 x 10' 1.01 x i03 5.85 x 101
(1.38)
'UD, undetectable (see footnote a of Table 1).
bNumbers in parentheses are covalent binding index; value calculated according to Lutz (4).
CND, not determined (lost by accident).
slightly lowerthanthat inmacromolecules fromotheras- to EPAcomputations (12)], in the case ofliver DNA and
sayed organs. This could be due to either a partial loss kidney, and lung RNA, Saturation seems to occur at
ofbenzene viathe lungs and/orto ahigherdetoxification 0.623 mmole/kg (48.6 mg/kg) (approximately 60 ppm by
in that organ. The active metabolite could be formed in inhalation), in the case ofliver RNA and liver, kidneyand
the liver and it could be sufficiently stable to reach ex- lungproteins. All otherrelationships arelinearwithinthe
trahepatic target sites. Previous work (5) showed that whole range of sensitivity of the technique. However,
only hepatic microsomes are capable ofbioactivatingben- resultsreportedhere arenotquite comparable withthose
zene. Inthat same study(5), '4C-benzenebindingto DNA obtainedfrom inhalation-administeredanimals thatwere
in the mouse bone marrow reached values similar to kept in a chamber with a constant concentration ofben-
those detected in theliver DNA, whereas the labelingof zene. Moreover, we are aware that chronic administra-
ratbone marrowwas evenfive times higher thanthatof tion of benzene could affect the number of adducts
liver DNA. formed, especially at the highest dosages.
The present study further supports the evidence of The relationship between adduct formation to DNA,
saturation ofbenzene metabolism at the upper doses (in RNA, and protein of the assayed organs and benzene-
the 10-100 ppmrange), aspreviously discussed byGrilli administered dose stayed linear within a wide range of
et al. (2) and confirmed by Parodi et al. (11). The satura- dosages less than 48.6 mg/kg. The behavior ofbenzene,
tionlevel corresponds to 6.23mmole/kg(486 mg/kg)body a weak genotoxic compound, resembles that of potent
weight [approximately 600 ppm by inhalation according genotoxic compQunds that belong to the main classes of
Table 6. Dose-response relationship of in vivo binding of 3H-benzene to biological macromolecules from rat lung.
Adducts, pmole/mg
Dose, mmole/kg DNA RNA Protein
1.73 x 10- 7 UDa UD UD
1.04 x 10-6 UD 4.21 x 10-5 UD
6.23 x 10-6 UD 4.34 x 10-4 1.71 x 10-4
1.97 x 10-' 3.33 x 10-5 NDc ND
(0.55)b
6.23 x 10- 4.42 x 10-4 4.02 x 10- 9.65 x 10-4
(2.31)
6.23 xl-i4 5.00 x 10-4 4.11 x 10-2 9.51 x 10-'
(0.26)
6.23 x l03 1.40 x 10-2 5.19 x 10 1.30 x 10-'
(0.73)
6.23 x 10-2 1.54 x 10-' 2.11 x 10' 1.51
(0.80)
6.23 x 10- 1.16 4.52 x 10' 7.76
(0.61)
6.23 2.03 x 101 1.61 x 102 1.95 x 10'
(1.06)
aljD, undetectable (see footnote a of Table 1).
bNumbers in parentheses are covalent binding index; value calculated according to Lutz (4).
CND, not determined (lost by accident).
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Table 7. Evidence of linear relationship between administered dose of carcinogen and amount of its DNA adducts.
Range of assayed dose,
Route of administration mole/kg, with linear
Compound and speciesa dose-response relationship Organ Reference
t-4-Acetylaminostilbeneb PO, rat 5 x 10- 1°-5 x 10-7 Liver (7)
t-4-Dimethylaminostilbene PO, rat 5 x 10- 10_10 -4 Liver, kidney (7)
2-Acetylaminofluorenec PO, rat 10 -6_1-4 Liver (21)
Diethynitrosamine IP, rat 1.2 x 10-4-2 x 10-3 Liver (22)
Dimethylnitrosamine PO, rat 10 -8_10-6 Liver (23)
10 -81_o - 4 Kidney
Dimethylnitrosamined IP, rat 6.8 x 10-6-3.4 x 10-4 Liver (24)
Benzo[a]pyrene PO, mouse 10 9-iO-4 Liver (25)
l0-9-io-5 Stomach
Benzo[a]pyrene PO, mouse 1.2 x 10-66 x 10-4 Liver, lung (26)
Benzo[a]pyrene PC, mouse 1.6 x 10-9-4.8 x 10-5 Skin (27)
7,12-Dimethylbenz[a]anthracene PC, mouse 10-6-4 x 10-' Skin (27)
Aflatoxin B, IP, rat 3 x 10-"-10-9 Liver (28)
Aflatoxin B1 PO, rat 3.2 x 10-2-3.2 x 10-7 Liver (4)
Benzene IP, rat 6.23 x 10-9-6.23 x 10-4 Liver Data from
1.97 x 10-8-6.23 x 10-3 Lung this paper
6.23 x 10-8-6.23 x 10-3 Kidney
6.23 x 10-9-6.23 x 10-3 Spleen, stomach
apo, per os; IP, intraperitoneally; PC, percutaneously.
bBinding to liver, kidney, stomach, and lung DNA linearly increases afterrepeated administration (twelve 5 x 10 -6 mole/kg doses within 40 days).
cWund-Bisseret et al. (20) found a sublinear shape after IP injection to rat liver, decreasing from 4.7 x 10- 6 to 7 x 10 9 mole/kg; binding values
were lowered by 29-fold (from 3.178 to 0.109 nmole/mg DNA).
d7-Methylguanine production is linear up to 1.4 x 10 7 mole/kg; 06-methylguanine formation is sublinear within 6.8 x 10 -6 and 1.4 x 10-7 mole/kg.
'At the dose 3 x 10-9 mole/kg, a flattening of the curves occurs (saturation effect).
chemical carcinogens and require metabolic activation
(Table 7). Different shape was observed in the dose-
response function offormaldehyde, adirectly actingsub-
stance: Linearity was found with protein adducts and
sublinearity with DNA adducts (13). On the other hand,
a flattening ofthe curve ofadducts versus dose function
hasbeen shownforothercarcinogens, such asvinyl chlo-
ride(14). Whenthefractionofanimalswithvinyl chloride-
induced angiosarcomas was considered and plotted as a
function ofDNA adducts, an almostlinear curve was ob-
tained (15), thus showing a good correlation between
metabolite production and carcinogenic action.
Experimental data concerning metabolic activation and
mechanisms ofaction ofcarcinogens are needed in order
to improve the evaluation ofhuman risk (3,16). Indeed,
the available mathematical models (linear Weibull, logit,
probit, multistage, gamma multihit, one-hit) give con-
trasting information about risk from both occupational
and environmental exposure. The degree ofuncertainty
from the mathematical approaches could be reduced by
using data reported here. As previously reported, the
curve representing tumor induction as a function ofhu-
man occupational exposure to benzene shows a flatten-
ingatthe highest doses(2). Arecent report onhuman ex-
posure to benzene at slightly lower occupational doses
seems to indicate a sublinearrelationship(17). The study
by Rinsky et al. (1 )is veryimportantbecause it accounts
for an increased risk of death from leukemia even at 1
ppm(40-yearexposure) (that is at anexposure levellower
than thatpreviously explored in human studies) and sug-
gests that a reduction in the permissible exposure limits
(TLV) needs to be performed.
The shape ofthe function obtained by logistic regres-
sionanalysis, which couldgive ariskestimate lowerthan
that expected from a linear extrapolation at low doses,
is notyet sufficiently supported bythe scanty number of
tumors observed at the lowest exposure levels. Promo-
tionlike effects could accountfor such a sublinear shape.
However, dose-response curvesmaybelinear also atlow
doses, especially those lower than 1 ppm for a working
life, when promotion does not play a prominent role.
The problem ofwhether the response to alow-dose ex-
posure is linear or sublinear is very important because
the number of people exposed at low doses as a conse-
quence ofenvironmental contaminationisveryhigh(18).
However, the estimate ofriskassociated to environmen-
tal exposure, which is much less than occupational ex-
posure, would not be based on direct epidemiological or
experimental Gong-term assay) data. Therefore, we sug-
gest that a linear extrapolation couldbe used to quantify
the associatedrisktothelowestlevelsofexposuretoben-
zene, starting from the lowest dosages leading to a
statistically signiflcant increase of tumor incidence.
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